Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Geron Corporation - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
GERN
Nasdaq
2830
www.geron.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Geron Corporation
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
- Jun 1st, 2026 6:00 am
Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- May 19th, 2026 7:35 am
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- May 18th, 2026 2:01 pm
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026
- May 12th, 2026 7:31 am
Is Geron (GERN) One of the Best US Stocks Under $5 to Buy?
- May 11th, 2026 3:21 pm
A Look At Geron (GERN) Valuation After Q1 Results And Reaffirmed 2026 Guidance
- May 8th, 2026 7:17 am
Geron Corporation (NASDAQ:GERN) Just Reported And Analysts Have Been Lifting Their Price Targets
- May 8th, 2026 7:02 am
Geron Corporation Q1 2026 Earnings Call Summary
- May 7th, 2026 6:30 am
Geron Q1 Earnings Call Highlights
- May 6th, 2026 7:07 am
Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates
- May 6th, 2026 6:25 am
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
- May 6th, 2026 5:00 am
Geron Plans to Present at Upcoming Investor Conferences
- May 5th, 2026 6:00 am
Geron Corporation (GERN) Appoints Timothy Williams as EVP, Chief Legal Officer
- Apr 25th, 2026 3:06 pm
Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026
- Apr 22nd, 2026 5:00 am
Geron Adds Chief Legal Officer As Equity Ties To Execution Risk
- Apr 14th, 2026 6:14 pm
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Apr 14th, 2026 2:05 pm
Geron Highlights RYTELO Launch, 2026 Revenue Outlook and Phase 3 Myelofibrosis Plans at Needham Conf
- Apr 13th, 2026 7:32 pm
Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary
- Apr 13th, 2026 6:00 am
Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference
- Apr 6th, 2026 6:00 am
Geron Adds Biopharma Veterans As RYTELO Focus And Valuation Draw Attention
- Mar 28th, 2026 11:03 pm
Scroll